C Nieder

Summary

Affiliation: Nordland Hospital
Country: Norway

Publications

  1. doi Impact of systemic treatment on survival after whole brain radiotherapy in patients with brain metastases
    Carsten Nieder
    Department of Oncology and Palliative Medicine, Nordland Hospital, 8092, Bodø, Norway
    Med Oncol 31:927. 2014
  2. ncbi Active anticancer treatment during the final month of life in patients with non-small cell lung cancer
    Carsten Nieder
    Department of Oncology and Palliative Medicine, Nordland Hospital, P O Box 1480, 8092 Bodø, Norway
    Anticancer Res 34:1015-20. 2014
  3. ncbi Development and validation of a model predicting short survival (death within 30 days) after palliative radiotherapy
    Kent Angelo
    Department of Oncology and Palliative Medicine, Nordland Hospital, 8092 Bodø, Norway
    Anticancer Res 34:877-85. 2014
  4. doi Presentation, patterns of care, and survival in patients with brain metastases: what has changed in the last 20 years?
    Carsten Nieder
    Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway Institute of Clinical Medicine, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway
    Cancer 117:2505-12. 2011
  5. doi Radiotherapy versus best supportive care in patients with brain metastases and adverse prognostic factors
    Carsten Nieder
    Department of Oncology and Palliative Medicine, Nordland Hospital, 8092, Bodø, Norway
    Clin Exp Metastasis 30:723-9. 2013
  6. doi Best supportive care in patients with brain metastases and adverse prognostic factors: development of improved decision aids
    Carsten Nieder
    Department of Oncology and Palliative Medicine, Nordland Hospital, 8092, Bodø, Norway
    Support Care Cancer 21:2671-8. 2013
  7. pmc Continuous controversy about radiation oncologists' choice of treatment regimens for bone metastases: should we blame doctors, cancer-related features, or design of previous clinical studies?
    Carsten Nieder
    Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, 8092, Norway
    Radiat Oncol 8:85. 2013
  8. doi Contribution of case reports to glioblastoma research: systematic review and analysis of pattern of citation
    Carsten Nieder
    Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway
    Br J Neurosurg 26:809-12. 2012
  9. doi Does overall treatment time impact on survival after whole-brain radiotherapy for brain metastases?
    C Nieder
    Department of Oncology and Palliative Medicine, Nordland Hospital, Bodo, Norway
    Clin Transl Oncol 13:885-8. 2011
  10. pmc Brain metastases research 1990-2010: pattern of citation and systematic review of highly cited articles
    Carsten Nieder
    Department of Oncology and Palliative Medicine, Nordland Hospital, 8092 Bodø, Norway
    ScientificWorldJournal 2012:721598. 2012

Detail Information

Publications109 found, 100 shown here

  1. doi Impact of systemic treatment on survival after whole brain radiotherapy in patients with brain metastases
    Carsten Nieder
    Department of Oncology and Palliative Medicine, Nordland Hospital, 8092, Bodø, Norway
    Med Oncol 31:927. 2014
    ..The exact magnitude of improvement can only be assessed in randomized trials because retrospective cohort studies, even if carefully designed, are not able to correct for all potential imbalances...
  2. ncbi Active anticancer treatment during the final month of life in patients with non-small cell lung cancer
    Carsten Nieder
    Department of Oncology and Palliative Medicine, Nordland Hospital, P O Box 1480, 8092 Bodø, Norway
    Anticancer Res 34:1015-20. 2014
    ....
  3. ncbi Development and validation of a model predicting short survival (death within 30 days) after palliative radiotherapy
    Kent Angelo
    Department of Oncology and Palliative Medicine, Nordland Hospital, 8092 Bodø, Norway
    Anticancer Res 34:877-85. 2014
    ..Our model might support decision-making (best supportive care versus PRT) and is the first decision aid specifically addressing PRT near end of life. ..
  4. doi Presentation, patterns of care, and survival in patients with brain metastases: what has changed in the last 20 years?
    Carsten Nieder
    Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway Institute of Clinical Medicine, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway
    Cancer 117:2505-12. 2011
    ..It is largely unknown to what extent new oncologic treatment options have improved survival of patients with brain metastasis in recent decades. Therefore, a multi-institutional time-staggered analysis was performed...
  5. doi Radiotherapy versus best supportive care in patients with brain metastases and adverse prognostic factors
    Carsten Nieder
    Department of Oncology and Palliative Medicine, Nordland Hospital, 8092, Bodø, Norway
    Clin Exp Metastasis 30:723-9. 2013
    ..g. by refining available survival prediction tools, and to confirm that management of those with small cell lung cancer should include a less restricted use of WBRT...
  6. doi Best supportive care in patients with brain metastases and adverse prognostic factors: development of improved decision aids
    Carsten Nieder
    Department of Oncology and Palliative Medicine, Nordland Hospital, 8092, Bodø, Norway
    Support Care Cancer 21:2671-8. 2013
    ..This study aimed to develop a survival prediction model that might aid decision making when choosing between best supportive care (BSC) and brain radiotherapy (RT) for patients with brain metastases and limited survival expectation...
  7. pmc Continuous controversy about radiation oncologists' choice of treatment regimens for bone metastases: should we blame doctors, cancer-related features, or design of previous clinical studies?
    Carsten Nieder
    Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, 8092, Norway
    Radiat Oncol 8:85. 2013
    ..because of challenging disease extent. We identify open questions and provide research suggestions, which might contribute to making radiation oncology practitioners more confident in selecting the right treatment for the right patient...
  8. doi Contribution of case reports to glioblastoma research: systematic review and analysis of pattern of citation
    Carsten Nieder
    Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway
    Br J Neurosurg 26:809-12. 2012
    ..Little is known about their influence on advancement of the field or scientific merits. Do glioblastoma case reports attract attention or do they go largely unrecognized?..
  9. doi Does overall treatment time impact on survival after whole-brain radiotherapy for brain metastases?
    C Nieder
    Department of Oncology and Palliative Medicine, Nordland Hospital, Bodo, Norway
    Clin Transl Oncol 13:885-8. 2011
    ..While survival might be largely independent from OTT, it should also be evaluated whether this parameter has any impact on quality of life and duration of palliation...
  10. pmc Brain metastases research 1990-2010: pattern of citation and systematic review of highly cited articles
    Carsten Nieder
    Department of Oncology and Palliative Medicine, Nordland Hospital, 8092 Bodø, Norway
    ScientificWorldJournal 2012:721598. 2012
    ..Different measures of impact, visibility, and quality of published research are available, each with its own pros and cons. For this overview, article citation rate was chosen...
  11. doi Brain metastases in patients under 50 years of age: retrospective analysis
    Carsten Nieder
    Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway
    Clin Exp Metastasis 29:949-56. 2012
    ..Nevertheless, further efforts are necessary to improve long-term survival...
  12. ncbi Highly cited German research contributions to the fields of radiation oncology, biology, and physics: focus on collaboration and diversity
    C Nieder
    Department of Oncology and Palliative Medicine, Nordland Hospital, 8092 Bodø, Norway
    Strahlenther Onkol 188:865-72. 2012
    ..Therefore, a systematic review was performed of successfully completed research that had a high impact on clinical practice. These data might be helpful when preparing new projects...
  13. doi Non-small cell lung cancer histological subtype has prognostic impact in patients with brain metastases
    Carsten Nieder
    Department of Oncology and Palliative Medicine, Nordland Hospital, 8092, Bodø, Norway
    Med Oncol 29:2664-8. 2012
    ..However, the gap has widened in recently treated patients. Comparable to patients without brain metastases, primary tumour histology should be taken into account when assessing patients' prognosis and recommending treatment strategy...
  14. doi Glioblastoma research 2006-2010: pattern of citation and systematic review of highly cited articles
    Carsten Nieder
    Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway
    Clin Neurol Neurosurg 114:1207-10. 2012
    ..A large variety of preclinical and clinical topics achieved at least 25 citations. However, areas such as quality of life, side effects, and end-of-life care were underrepresented. Efforts to increase their visibility might be warranted...
  15. pmc Towards improved prognostic scores predicting survival in patients with brain metastases: a pilot study of serum lactate dehydrogenase levels
    Carsten Nieder
    Department of Oncology and Palliative Medicine, Nordland Hospital, 8092 Bodø, Norway
    ScientificWorldJournal 2012:609323. 2012
    ..Based on these encouraging results, confirmatory studies in a larger cohort of patients are warranted...
  16. pmc Contribution of case reports to brain metastases research: systematic review and analysis of pattern of citation
    Carsten Nieder
    Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway
    PLoS ONE 7:e34300. 2012
    ..Apparently, case reports describing unexpected therapeutic success gain more attention, at least in terms of citation, than others...
  17. doi Adding cetuximab to stereotactic radiotherapy for non-small cell lung cancer might reduce local failure rates
    Carsten Nieder
    Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway
    Med Hypotheses 78:420-2. 2012
    ..If improved local control rates could be observed, overall survival might improve accordingly...
  18. pmc A review of clinical trials of cetuximab combined with radiotherapy for non-small cell lung cancer
    Carsten Nieder
    Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway
    Radiat Oncol 7:3. 2012
    ..Nevertheless, combined treatment appears feasible. The role of consolidation cetuximab after RT is uncertain. A large randomised phase III study of combined RT, chemotherapy and cetuximab has been initiated...
  19. doi Colorectal cancer metastatic to the brain: time trends in presentation and outcome
    Carsten Nieder
    Department of Internal Medicine, Division of Oncology and Palliative Medicine, Nordlandssykehuset HF, Bodø, Norway
    Oncology 76:369-74. 2009
    ..It was the aim of this study to compare differences in disease pattern, patient characteristics and survival in patient cohorts treated during different decades...
  20. ncbi Detrimental effects of an antibody directed against tumor necrosis factor alpha in experimental kidney irradiation
    Carsten Nieder
    Department of Internal Medicine Oncology, Radiation Oncology Unit, Nordlandssykehuset HF, Bodø, Norway
    Anticancer Res 27:2353-7. 2007
    ..These data suggest that administration of infliximab concomitant to radiotherapy causes profound alterations in the development of kidney dysfunction. Importantly, other radiation-related toxicities were similar across all groups...
  21. ncbi Analysis of long-term survivors of glioblastoma multiforme in a single institution with aggressive local retreatment protocol
    Carsten Nieder
    Radiation Oncology Unit, Nordlandssykehuset HF, 8092 Bodo, Norway
    Anticancer Res 27:2993-6. 2007
    ..Our institution has used an aggressive policy of local retreatment, including surgery and radiotherapy, at first relapse. Long-term survival (>2 years) after such an approach was evaluated...
  22. ncbi Validation of the graded prognostic assessment index for surgically treated patients with brain metastases
    Carsten Nieder
    Medical Department, Radiation Oncology Unit, Nordlandssykehuset HF, Bodø, Norway
    Anticancer Res 28:3015-7. 2008
    ..9, 9.8, 5.5, and 3.7 months, respectively (p<0.05). In conclusion, these results confirm the validity of the GPA index in a patient population that previously has not been assessed with this new tool...
  23. pmc Experimental concepts for toxicity prevention and tissue restoration after central nervous system irradiation
    Carsten Nieder
    Radiation Oncology Unit, Nordlandssykehuset HF, 8092 Bodø, Norway
    Radiat Oncol 2:23. 2007
    ....
  24. ncbi Evaluation of late neurologic adverse events in patients with brain metastases from non-small cell lung cancer
    Carsten Nieder
    Department of Internal Medicine Oncology, Radiation Oncology Unit, Nordlandssykehuset HF, Bodø, Norway
    Anticancer Res 27:1701-4. 2007
    ....
  25. pmc Influence of different treatment techniques on radiation dose to the LAD coronary artery
    Carsten Nieder
    Radiation Oncology Unit, Nordlandssykehuset HF, 8092 Bodø, Norway
    Radiat Oncol 2:20. 2007
    ..Radiation-induced heart disease might be a serious complication in long-term cancer survivors...
  26. pmc Prognostic scores in brain metastases from breast cancer
    Carsten Nieder
    Radiation Oncology Unit, Nordlandssykehuset HF, Bodø, Norway
    BMC Cancer 9:105. 2009
    ..The available scores for patients with brain metastases have never been tested specifically in patients with primary breast cancer. It is therefore unknown which score is most appropriate for these patients...
  27. ncbi Disease presentation and outcome in very young patients with brain metastases from breast cancer
    Carsten Nieder
    Radiation Oncology Unit, Department of Internal Medicine, Nordlandssykehuset HF, Bodø, Norway
    Tumori 94:691-3. 2008
    ..Little information is available on disease presentation and treatment outcome in very young patients with brain metastases from breast cancer. Therefore, we evaluated our results in this group...
  28. doi Effects of smoking cessation on hypoxia and its potential impact on radiation treatment effects in lung cancer patients
    Carsten Nieder
    Radiation Oncology Unit, Medical Department, Nordlandssykehuset HF, Bodø, Norway
    Strahlenther Onkol 184:605-9. 2008
    ....
  29. ncbi Radiation therapy plus angiogenesis inhibition with bevacizumab: rationale and initial experience
    Carsten Nieder
    Radiation Oncology Unit, Department of Internal Medicine and Skin Diseases, Nordlandssykehuset HF, 8092 Bodø, Norway
    Rev Recent Clin Trials 2:163-8. 2007
    ..Early results suggest that acute toxicity is acceptable, planned surgery after such treatment is feasible, and that further evaluation of such combined modality treatment is warranted...
  30. doi Prediction of very short survival in patients with brain metastases from breast cancer
    C Nieder
    Radiation Oncology Unit, Nordlandssykehuset HF, 8092 Bodø, Norway
    Clin Oncol (R Coll Radiol) 20:337-9. 2008
    ..e. <2 months, who are unlikely to derive major benefit from whole brain radiotherapy. Our aim was to develop a more reliable model...
  31. doi Improvement, clinical course, and quality of life after palliative radiotherapy for recurrent glioblastoma
    Carsten Nieder
    Department of Internal Medicine Oncology and Radiation Oncology Units, Nordlandssykehuset HF, Bodø, Norway
    Am J Clin Oncol 31:300-5. 2008
    ..Salvage chemotherapy or targeted agents should be prospectively tested against re-irradiation alone...
  32. doi Is whole-brain radiotherapy effective and safe in elderly patients with brain metastases?
    Carsten Nieder
    Radiation Oncology Unit, Nordlandssykehuset HF, Bodø, Norway
    Oncology 72:326-9. 2007
    ..The outcome of whole-brain radiotherapy in elderly patients with brain metastases is not well documented. As the number of such patients is expected to increase, we evaluated our results...
  33. doi Disease presentation and treatment outcome in very young patients with brain metastases from lung cancer
    Carsten Nieder
    Radiation Oncology Unit, Nordlandssykehuset HF, Bodø, Norway
    Onkologie 31:305-8. 2008
    ..While elderly patients with brain metastases from lung cancer appear to have an unfavorable prognosis, little information is available on disease presentation and treatment outcome in very young patients...
  34. pmc An uncommon presentation and course of metastatic malignant melanoma: a case report
    Astrid Dalhaug
    Radiation Oncology Unit, Department of Internal Medicine and Skin Diseases, Nordlandssykehuset HF, 8092 Bodø, Norway
    J Med Case Reports 1:151. 2007
    ..This case illustrates that some patients with multi-organ melanoma manifestations may benefit from the repeated use of effective local therapeutic approaches and may experience a quite favourable prognosis...
  35. pmc Presentation and course of brain metastases from breast cancer in a paranoid-schizophrenic patient: A case report
    Astrid Dalhaug
    Radiation Oncology Unit, Medical Department, Nordlandssykehuset HF, 8092 Bodø, Norway
    Cases J 1:195. 2008
    ..Treatment consisted of whole-brain radiotherapy and letrozole. Twenty-one months later, the patient is in continued partial remission...
  36. ncbi The role of postoperative radiotherapy after resection of a single brain metastasis. Combined analysis of 643 patients
    Carsten Nieder
    Radiation Oncology Unit, Department of Internal Medicine, Nordlandssykehuset HF, Bodø, Norway
    Strahlenther Onkol 183:576-80. 2007
    ....
  37. doi Estimating need for palliative external beam radiotherapy in adult cancer patients
    Carsten Nieder
    Division of Hematology and Oncology, Department of Internal Medicine, Nordlandssykehuset HF Hospital, Bodø, Norway
    Int J Radiat Oncol Biol Phys 76:207-11. 2010
    ..The corresponding number for Norway was 95 (95% CI 93-98) in 2004. New data are lacking, although new systemic treatment options might alter this number...
  38. doi Resource utilization in patients with brain metastases managed with best supportive care, radiotherapy and/or surgical resection: a Markov analysis
    Carsten Nieder
    Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway
    Oncology 78:348-55. 2010
    ..In spite of the large number of patients and increasing financial pressure on health care budgets worldwide, limited data on resource utilization after diagnosis of brain metastases are available...
  39. ncbi Impact of common medications on serum total prostate-specific antigen levels and risk group assignment in patients with prostate cancer
    Carsten Nieder
    Department of Oncology and Palliative Medicine, Nordland Hospital, Bodo, Norway
    Anticancer Res 31:1735-9. 2011
    ..These results support the concerns expressed previously, given that risk group assignment, which may be inaccurate in patients using concomitant medications, eventually guides choice of treatment...
  40. doi Can current prognostic scores reliably guide treatment decisions in patients with brain metastases from malignant melanoma?
    Carsten Nieder
    Department of Oncology and Palliative Medicine, Radiation Oncology Unit, Nordland Hospital, Bodø, Norway
    J Cancer Res Ther 7:47-51. 2011
    ....
  41. doi Combined radio- and chemotherapy of brain tumours in adult patients
    C Nieder
    Radiation Oncology Unit, Nordland Hospital, Bodø, Norway
    Clin Oncol (R Coll Radiol) 21:515-24. 2009
    ..The challenges associated with brain tumour treatment remain formidable, but rationally designed clinical trials are gradually leading to improved outcomes...
  42. pmc Pathologic fracture and metastatic spinal cord compression in patients with prostate cancer and bone metastases
    Carsten Nieder
    Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway
    BMC Urol 10:23. 2010
    ..The purpose of this study was to determine the risk factors for and incidence as well as prognostic impact of pathologic fracture (PF) and metastatic spinal cord compression (MSCC) in patients with bone metastases (BM) from prostate cancer...
  43. doi Advances in translational research provide a rationale for clinical re-evaluation of high-dose radiotherapy for glioblastoma
    Carsten Nieder
    Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway
    Med Hypotheses 76:410-3. 2011
    ..Additional drugs targeting other pathways and microenvironmental features such as invasion, oxygenation and blood supply, might be included in the rational design of future clinical trials, provided initial studies support their use...
  44. ncbi A population-based study of the pattern of terminal care and hospital death in patients with non-small cell lung cancer
    Carsten Nieder
    Department of Oncology and Palliative Medicine, Nordland Hospital, P O Box 1480, 8092 Bodø, Norway
    Anticancer Res 32:189-94. 2012
    ..Patients with T4 tumors might experience unsatisfactory symptom control and should be offered a part in prospective studies addressing these issues...
  45. doi Postoperative treatment and prognosis of patients with resected single brain metastasis: how useful are established prognostic scores?
    Carsten Nieder
    Department of Oncology and Palliative Medicine, Nordland Hospital, 8092 Bodø, Norway
    Clin Neurol Neurosurg 113:98-103. 2011
    ..To evaluate postoperative prognosis and the performance of known prognostic scores in patients treated with surgical resection for single brain metastasis...
  46. doi Comorbidity, use of common medications, and risk of early death in patients with localized or locally advanced prostate cancer
    Carsten Nieder
    Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway
    ScientificWorldJournal 11:1178-86. 2011
    ..Our data suggest that simple parameters such as use of medications vs. none, or presence of serious cardiac disease vs. none, are not sufficient, and that age-adjusted CCI scores outperform the other factors included in our analysis...
  47. ncbi Disease presentation and outcome in young patients (<40 years) with brain metastases from malignant melanoma
    Carsten Nieder
    Medical Department Oncology, Nordlandssykehuset HF, Bodø, Norway
    Anticancer Res 28:1325-7. 2008
    ..Whole-brain radiation therapy was not able to provide durable CNS control. Prospective studies on treatment intensification appear warranted...
  48. ncbi Does distance to treatment centre influence the rate of palliative radiotherapy in adult cancer patients?
    Carsten Nieder
    Radiation Oncology Unit, Department of Internal Medicine, Nordlandssykehuset HF, 8092 Bodø, Norway
    Anticancer Res 29:2641-4. 2009
    ..In conclusion, these data suggest that the utilisation of palliative radiotherapy in a health care system without financial barriers to treatment no longer varies with distance between residence and hospital...
  49. doi Prognostic scores in patients with brain metastases from non-small cell lung cancer
    Carsten Nieder
    Radiation Oncology Unit, Department of Internal Medicine Oncology, Nordland Hospital, Bodø, Norway
    J Thorac Oncol 4:1337-41. 2009
    ..No comparison to the two NSCLC-specific scores has been made either. Hence, it remains unclear which score is most appropriate for these patients...
  50. doi Prediction of short survival in patients with brain metastases based on three different scores: a role for 'triple-negative' status?
    C Nieder
    Radiation Oncology Unit, Nordland Hospital, Bodø, Norway Institute of Clinical Medicine, Faculty of Medicine, University of Tromsø, Tromsø, Norway
    Clin Oncol (R Coll Radiol) 22:65-9. 2010
    ..To evaluate models predicting short survival in patients with brain metastases treated with whole-brain radiotherapy (WBRT)...
  51. doi Treatment of brain metastases from renal cell cancer
    Carsten Nieder
    Department of Internal Medicine, Division of Oncology, Nordland Hospital, Bodø, Norway
    Urol Oncol 29:405-10. 2011
    ..To evaluate disease pattern, patient characteristics, and survival in patients treated for brain metastases from renal cell carcinoma...
  52. doi Validation of new prognostic and predictive scores by sequential testing approach
    Carsten Nieder
    Radiation Oncology Unit, Department of Oncology and Palliative Care, Nordland Hospital, Bodø, Norway
    Strahlenther Onkol 186:169-73. 2010
    ..The present study evaluates this approach in scores related to radiation oncology...
  53. ncbi A new prognostic score derived from phase I study participants with advanced solid tumours is also valid in patients with brain metastasis
    Carsten Nieder
    Radiation Oncology Unit, Department of Oncology and Palliative Medicine, Nordland Hospital, 8092 Bodø, Norway
    Anticancer Res 30:977-9. 2010
    ..Its performance should be evaluated in larger groups of patients and head to head comparisons of the established brain metastases scores with this new model should be made...
  54. doi Use of the Graded Prognostic Assessment (GPA) score in patients with brain metastases from primary tumours not represented in the diagnosis-specific GPA studies
    C Nieder
    Department of Oncology and Palliative Medicine, Nordland Hospital, 8092, Bodø, Norway
    Strahlenther Onkol 188:692-5. 2012
    ..However, patients with unknown or rare primary tumours are not represented in this model. A pragmatic approach might be use of the first GPA version which is not limited to specific primary tumours...
  55. ncbi Sunitinib, sorafenib, temsirolimus or bevacizumab in the treatment of metastatic renal cell carcinoma: a review of health economic evaluations
    J Norum
    Department of Clinical Medicine, Faculty of Health Sciences, University of Tromsø, Norway
    J Chemother 22:75-82. 2010
    ..When compared to the other agents, sunitinib has the best cost-effectiveness figure. Second-line therapy does not offer valid incremental cost-effectiveness ratios...
  56. pmc Leptomeningeal carcinomatosis from renal cell cancer: treatment attempt with radiation and sunitinib (case report)
    Astrid Dalhaug
    Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway
    World J Surg Oncol 8:36. 2010
    ..The untreated lung metastases progressed very slowly during almost 3 years of observation. This case illustrates important issues around both biological behaviour and treatment approaches in metastatic renal cell cancer...
  57. doi Validation of the graded prognostic assessment index for patients with brain metastases
    Carsten Nieder
    Medical Department, Radiation Oncology Unit, Nordlandssykehuset HF, Bodø, Norway
    Acta Oncol 48:457-9. 2009
    ....
  58. pmc Anaemia and thrombocytopenia in patients with prostate cancer and bone metastases
    Carsten Nieder
    Department of Internal Medicine Division of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway
    BMC Cancer 10:284. 2010
    ..The purpose of this study was to determine the incidence, risk factors and prognostic impact of anaemia and thrombocytopenia in patients with bone metastases (BM) from prostate cancer...
  59. pmc Can prophylactic breast irradiation contribute to cardiac toxicity in patients with prostate cancer receiving androgen suppressing drugs?
    Carsten Nieder
    Radiation Oncology Unit, Nordlandssykehuset HF, 8092 Bodø, Norway
    Radiat Oncol 3:2. 2008
    ..Possible explanations were provided, however, they disregard the potential contribution of prophylactic radiotherapy to the mamillary regions (PMRT, prescribed to avoid gynecomastia)...
  60. ncbi Late residual gamma-H2AX foci in murine spinal cord might facilitate development of response-modifying strategies: a research hypothesis
    Nicolaus Andratschke
    Department of Radiation Oncology, Klinikum rechts der Isar der Technischen Universitat Munchen, Munich, Germany
    Anticancer Res 31:561-4. 2011
    ..A rapid and reliable animal model would allow for screening of a large number of candidate drugs that might modify the radiation response of the spinal cord...
  61. pmc Prognostic indices for brain metastases--usefulness and challenges
    Carsten Nieder
    Medical Department, Division of Oncology, Nordland Hospital, 8092 Bodø, Norway
    Radiat Oncol 4:10. 2009
    ..e. between 1997 and 2008. In addition, other analyses of prognostic factors in groups of patients, which typically are underrepresented in large trials or databases, published in the same time period are reviewed...
  62. ncbi Treatment of newly diagnosed glioblastoma multiforme
    Carsten Nieder
    J Clin Oncol 20:3179-80; author reply 3181-2. 2002
  63. ncbi [Evaluation of the toxicity of tirapazamine plus cisplatin in a mouse tumor model]
    Markus Adam
    Praxis für Strahlentherapie und Radioonkologie, Röntgenstrasse 4, 82362 Weilheim
    Strahlenther Onkol 182:231-9. 2006
    ..The authors evaluated the toxicity of TPZ in combination with cisplatin in a mouse tumor model. For this purpose, general toxicity was monitored and all inner organs were examined histologically...
  64. ncbi Preclinical evaluation of erythropoietin administration in a model of radiation-induced kidney dysfunction
    Nicolaus Andratschke
    Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
    Int J Radiat Oncol Biol Phys 64:1513-8. 2006
    ..To test whether the clinically available growth factor erythropoietin (EPO) influences radiation-induced normal-tissue damage in a model of kidney dysfunction...
  65. ncbi Dose to the intracranial arteries in stereotactic and intensity-modulated radiotherapy for skull base tumors
    Carsten Nieder
    Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
    Int J Radiat Oncol Biol Phys 64:1055-9. 2006
    ..To examine retrospectively the maximum dose to the large skull base/intracranial arteries in fractionated stereotactic radiotherapy (FSRT) and intensity-modulated radiotherapy (IMRT), because of the potential risk of perfusion disturbances...
  66. ncbi Glioma treatment, radionecrosis, and growth factors. In regard to Levin et al., IJROBP 2002;53:58-66
    Carsten Nieder
    Int J Radiat Oncol Biol Phys 55:849; author reply 849. 2003
  67. ncbi Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy
    Anca L Grosu
    Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, 81675 Munich, Germany
    Int J Radiat Oncol Biol Phys 63:511-9. 2005
    ..To develop a valid treatment strategy for recurrent high-grade gliomas using stereotactic hypofractionated reirradiation based on biologic imaging and temozolomide...
  68. ncbi Simultaneous precise chemoradiation under inhalation anesthesia in an experimental mouse tumor model
    Markus Adam
    Radiotherapy Practice Weilheim, Röntgenstr 4, 82362 Weilheim, Germany
    Anticancer Res 25:2815-20. 2005
    ..p.) anesthesia. This is especially true for experiments where highly fractionated treatment schedules are used...
  69. ncbi Brain metastases in renal cell cancer: diagnostic and therapeutic aspects
    Carsten Nieder
    Department of Radiation Oncology, Klinikum rechts der Isar, Technical University Munich, Ismaninger Str 22, 81675 Munich, Germany
    Am J Clin Oncol 27:632-4. 2004
    ..However, further work-up revealed abscesses from bronchopneumonia. Diagnostic and therapeutic aspects as well as potential pitfalls in the management of patients with brain metastases are discussed...
  70. ncbi Treatment of unresectable glioblastoma multiforme
    Carsten Nieder
    Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, 81675 Munich, Germany
    Anticancer Res 25:4605-10. 2005
    ..Recent data suggest that class prediction models, based on defined molecular profiles, and assessment of MGMT promoter methylation might contribute to improved patient stratification and decision making...
  71. ncbi Necessity of identifying the patterns of failure after concurrent radiochemotherapy part of a combined modality approach in patients with stage III non-small cell lung cancer [Sakai et al., Lung Cancer 2004;43:195-201]
    Branislav Jeremic
    Lung Cancer 46:263-4. 2004
  72. ncbi Comparison of serum growth factors and tumor markers as prognostic factors for survival in non-small cell lung cancer
    Carsten Nieder
    Department of Radiation Oncology, Klinikum rechts der Isar, Technical University Munich, Ismaninger Str 22, 81675 Munich, Germany
    Anticancer Res 23:5117-23. 2003
    ..In virtually all large studies with multivariate analysis, their influence was higher than that of emerging factors...
  73. ncbi Radiation therapy alone as an alternative to surgery in patients with early stage non-small-cell lung cancer having cardiovascular (and other) comorbidity
    Branislav Jeremic
    Eur J Cardiothorac Surg 25:297. 2004
  74. ncbi Recursive partitioning analysis (RPA) class does not predict survival in patients with four or more brain metastases
    Carsten Nieder
    Department of Radiotherapy and Radiologic Oncology, Klinikum rechts der Isar, Technical University of Munich, Germany
    Strahlenther Onkol 179:16-20. 2003
    ..If up to three brain metastases are present, surgical resection or radiosurgery are currently being considered in case of favorable prognostic factors...
  75. ncbi Immunohistochemically detected p53 mutations in epithelial tumors and results of treatment with chemotherapy and radiotherapy. A treatment-specific overview of the clinical data
    Howard D Thames
    Department of Biomathematics, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Strahlenther Onkol 178:411-21. 2002
    ..The aim was to ascertain whether many hundreds of clinical reports over the last decade are consistent with the prediction of a poorer outcome in cancer patients with p53 abnormalities treated with cytotoxic drugs and radiation...
  76. ncbi Current status of angiogenesis inhibitors combined with radiation therapy
    Carsten Nieder
    Department of Radiation Oncology, Klinikum rechts der Isar der Technischen Universitat Munchen, Ismaninger Str 22, 81675 Munich, Germany
    Cancer Treat Rev 32:348-64. 2006
    ..Early results suggest that acute toxicity is acceptable, planned surgery after such treatment is feasible, and that further evaluation of such combined modality treatment is warranted...
  77. ncbi High-precision radiation therapy with integrated biological imaging and tumor monitoring: evolution of the Munich concept and future research options
    Anca L Grosu
    Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Germany
    Strahlenther Onkol 182:361-8. 2006
    ..To describe an emerging concept of high-precision radiotherapy, a modality characterized by adaptation to patient and organ movements, which might occur between fractions or even during radiation delivery...
  78. ncbi Extensive local and systemic therapy in extraneural metastasized glioblastoma multiforme
    Sabrina T Astner
    Department of Radiation Oncology, Technical University of Munich, Germany
    Anticancer Res 26:4917-20. 2006
    ..In conclusion, liver metastases of GBM can be effectively treated by chemotherapy. This case report suggests suitable substances which can be chosen according to clinical circumstances...
  79. ncbi Evaluation of insulin-like growth factor-1 in a mouse model of long-term abdominal radiation toxicity
    Carsten Nieder
    Department of Radiation Oncology, Klinikum rechts der Isar der Technischen Universitat Munchen, Munich, Germany
    Anticancer Res 27:183-7. 2007
    ....
  80. ncbi Influence of whole-brain radiotherapy on remission of brain metastases
    Carsten Nieder
    J Clin Oncol 24:4037; author reply 4037-8. 2006
  81. ncbi Stereotactic hypofractionated radiotherapy in stage I (T1-2 N0 M0) non-small-cell lung cancer (NSCLC)
    Frank B Zimmermann
    Department of Radiation Oncology, Klinikum rechts der Isar, Technical University, Munich, FRG
    Acta Oncol 45:796-801. 2006
    ..Hypofractionated SRT is safe even in elderly patients with stage I NSCLC and significantly reduced lung capacity. It leads to high local control rates and should be offered to patients not amenable for curative resection...
  82. ncbi Combined modality treatment of glioblastoma multiforme: the role of temozolomide
    Carsten Nieder
    Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Str 22, 81675 Munich, Germany
    Rev Recent Clin Trials 1:43-51. 2006
    ..The optimum schedule of temozolomide administration and the influence of combinations with additional antineoplastic agents remains to be studied. Early results of clinical trials addressing these issues are presented...
  83. ncbi Acceleration of normal-tissue damage expression by early stimulation of cell proliferation in rat spinal cord
    Carsten Nieder
    Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, 81675 Munich, Germany
    Strahlenther Onkol 182:680-4. 2006
    ..To examine experimental strategies for prevention of radiation-induced late spinal cord damage...
  84. ncbi What approach will lead to cure of glioblastoma multiforme? In regard to Barani et al. (Int J Radiat Oncol Biol Phys 2007;68:324-333) and Jones and Sanghera (Int J Radiat Oncol Biol Phys 2007;68:441-448)
    Carsten Nieder
    Int J Radiat Oncol Biol Phys 69:640-1; author reply 641. 2007
  85. ncbi Tirapazamine plus cisplatin and irradiation in a mouse model: improved tumor control at the cost of increased toxicity
    Markus Adam
    Radiotherapy Practice Weilheim, Weilheim, Germany
    J Cancer Res Clin Oncol 134:137-46. 2008
    ..Tirapazamine (TPZ) reportedly enhances the tumor cell killing effect of cisplatin up to fivefold and it is an attractive drug for combination with radiotherapy. We evaluated the toxicity of a fractionated combined treatment...
  86. ncbi Comparison of three different mediastinal radiotherapy techniques in female patients: Impact on heart sparing and dose to the breasts
    Carsten Nieder
    Department of Radiation Oncology, Klinikum rechts der Isar der Technischen Universitat Munchen, Munich, Germany
    Radiother Oncol 82:301-7. 2007
    ..Especially in highly curable diseases such as lymphoma, long-term survivors might develop late cardiac damage and radiation-induced second cancer...
  87. ncbi Radiotherapy-induced lung toxicity: risk factors and prevention strategies
    Carsten Nieder
    Department of Radiation Oncology, Klinikum rechts der Isar, Technical University Munich, Ismaninger Str 22, 81675 Munich, Germany
    Anticancer Res 23:4991-8. 2003
    ..This review summarizes translational research data as well as clinical strategies for response modification and prediction...
  88. ncbi Radiotherapy for high-grade gliomas. Does altered fractionation improve the outcome?
    Carsten Nieder
    Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Germany
    Strahlenther Onkol 180:401-7. 2004
    ..e., application of more than one fraction per day, in high-grade gliomas. This review summarizes the results of trials published between January 1997 and June 2002...
  89. ncbi 11C-methionine PET improves the target volume delineation of meningiomas treated with stereotactic fractionated radiotherapy
    Anca Ligia Grosu
    Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
    Int J Radiat Oncol Biol Phys 66:339-44. 2006
    ..To evaluate the role of 11C-methionine positron emission tomography (MET-PET) in target volume delineation for meningiomas and to determine the interobserver variability...
  90. ncbi The role of pentoxifylline as a modifier of radiation therapy
    Carsten Nieder
    Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Str 22, 81675 Munich, Germany
    Cancer Treat Rev 31:448-55. 2005
    ..It is therefore necessary to evaluate Ptx in larger clinical trials with less baseline variation and to improve the recording of long-term results...
  91. ncbi Does prophylactic breast irradiation in patients with prostate cancer influence cardiac toxicity?
    Carsten Nieder
    J Natl Cancer Inst 99:1646-7. 2007
  92. ncbi Implications of IMT-SPECT for postoperative radiotherapy planning in patients with gliomas
    Anca Ligia Grosu
    Klinik und Poliklinik für Strahlentherapie und Radiologische Onkologie, Klinikum rechts der Isar, Technische Universitat Munchen, Munchen, Germany
    Int J Radiat Oncol Biol Phys 54:842-54. 2002
    ..The goal of this study was to analyze the value of 123I-alpha-methyl-tyrosine-single photon emission CT (IMT-SPECT) in radiotherapy planning of patients with brain gliomas after surgical resection...
  93. ncbi Re-irradiation for recurrent head and neck cancer: in regard to Lee et Al. (Int j radiat oncol biol phys 2007;68:731-740)
    Carsten Nieder
    Int J Radiat Oncol Biol Phys 69:1652-3; author reply 1653. 2007
  94. ncbi [Experimental data for administration of insulin-like growth factor 1 (IGF-1) and basic fibroblast growth factor (bFGF) for prevention of radiation myelopathy]
    Carsten Nieder
    Klinik und Poliklinik für Strahlentherapie und Radiologische Onkologie, Technische Universitat, Klinikum rechts der Isar, Munchen
    Strahlenther Onkol 178:147-52. 2002
    ..Thus, we tested whether insulin-like growth factor-1 (IGF-1) and basic fibroblast growth factor (bFGF) alone or in combination modulate radiation tolerance of the rat cervical spinal cord...
  95. ncbi Salvage radiotherapy in patients with PET-Positive residual non-Hodgkin's lymphoma after chemotherapy: in regard to Kahn et al. (Int J Radiat Oncol Biol Phys 2006;66:961-965)
    Carsten Nieder
    Int J Radiat Oncol Biol Phys 67:1278; author reply 1278. 2007
  96. ncbi Proposal of human spinal cord reirradiation dose based on collection of data from 40 patients
    Carsten Nieder
    Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, 81675 Munich, Germany
    Int J Radiat Oncol Biol Phys 61:851-5. 2005
    ..However, prospective clinical studies are lacking. Therefore, a combined analysis of all published clinical data might provide a valuable basis for future trials...
  97. ncbi Therapeutic options for recurrent high-grade glioma in adult patients: recent advances
    Carsten Nieder
    Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Str 22, 81675 Munich, Germany
    Crit Rev Oncol Hematol 60:181-93. 2006
    ..Individual tailoring of such strategies based on molecular profiling is hoped to improve the outcome...
  98. ncbi Carcinomatous meningitis appearing as acoustic neuromas: two cases
    Sabrina T Astner
    Department of Radiation Oncology, Technical University of Munich, Germany
    Strahlenther Onkol 183:279-83. 2007
    ..If medical history does not match with acoustic neuroma, further diagnostics are necessary to rule out infectious disease or carcinomatous meningitis...
  99. ncbi Retreatment of the spinal cord with palliative radiotherapy
    Anca Ligia Grosu
    Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
    Int J Radiat Oncol Biol Phys 52:1288-92. 2002
    ..We conducted this retrospective review of patients whose spinal cord was irradiated twice to evaluate the outcome in terms of palliation and long-term side effects...
  100. ncbi Effects of insulin-like growth factor-1 (IGF-1) and amifostine in spinal cord reirradiation
    Carsten Nieder
    Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Germany
    Strahlenther Onkol 181:691-5. 2005
    ..Because of different modes of action, a follow-up study was undertaken to test the combined treatment...
  101. ncbi Update of human spinal cord reirradiation tolerance based on additional data from 38 patients
    Carsten Nieder
    Department of Radiation Oncology, Klinikum rechts der Isar der Technischen Universitat Munchen, Munich, Germany
    Int J Radiat Oncol Biol Phys 66:1446-9. 2006
    ..To update a combined analysis of all published clinical data...